| Symbol | A |
|---|---|
| Name | AGILENT TECHNOLOGIES, INC. |
| Sector | INDUSTRIALS |
| Region | North America |
| Industry | Biotechnology: Laboratory Analytical Instruments |
| Address | 5301 STEVENS CREEK BOULEVARD, SANTA CLARA, California, 95051, United States |
| Telephone | +1 800 227-9770 |
| Fax | — |
| — | |
| Website | https://www.agilent.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. Additional info from NASDAQ: |
Agilent Technologies, Inc. - Agilent Showcases Cancer Research Solutions at AACR 2026
Read moreHenson Meghan 🔴 sold 153 shares of AGILENT TECHNOLOGIES, INC. (A) at $113.98 Transaction Date: Mar 31, 2026 | Filing ID: 000040
Read moreAgilent Technologies, Inc. - Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader
Read moreNew Form SCHEDULE 13G/A - AGILENT TECHNOLOGIES, INC. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-000533 <b>Size:</b> 7 KB
Read moreAgilent Technologies, Inc. - Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
Read moreAgilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
Read moreDirector Rataj Sue H. 🟢 acquired 2.2K shares of AGILENT TECHNOLOGIES, INC. (A) at $111.75 Transaction Date: Mar 19, 2026 | Filing ID: 000039
Read more